Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Acquired Immunodeficiency Syndrome (AIDS) Market?
The size of the market for acquired immunodeficiency syndrome (AIDS) has seen substantial growth in recent years. The market size expansion is projected to continue from $32.09 billion in 2024 to $33.85 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.5%. The historical growth in the market can be credited to factors such as increasing HIV infection rates, more governmental funding dedicated to HIV therapies, the broadening scope of global awareness programs, enhancements in diagnostic abilities, and amplified backing from non-governmental organizations.
What Growth Rate Is Forecasted for the Acquired Immunodeficiency Syndrome (AIDS) Market by 2029?
The market for Acquired Immunodeficiency Syndrome (AIDS) is set for robust expansion over the coming years, with projections forecasting growth to $41.57 billion in 2029. This signifies a compound annual growth rate (CAGR) of 5.3%. The anticipated surge over the forecast period can be attributed to factors like the escalating demand for long-acting injectable treatments, increased use of pre-exposure prophylaxis (PrEP), heightened investment in HIV cure research, the proliferation of telemedicine services tailored for HIV care, a shifting emphasis towards personalised healthcare, and heightened awareness around the importance of early HIV detection. The forecast period is expected to be characterised by major trends, including a move towards single-tablet prescriptions, rising preference towards injectable and implantable HIV drugs, an increased need for digital health solutions in HIV management, burgeoning interest in functional HIV cure methods, and the widening application of artificial intelligence technologies in drug discovery.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
Which Key Companies Are Shaping the Future of the Acquired Immunodeficiency Syndrome (AIDS) Market?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
Which Factors Are Driving Demand in the Acquired Immunodeficiency Syndrome (AIDS) Industry?
The growth of the acquired immunodeficiency syndrome (AIDS) market is projected to accelerate due to rising rates of HIV infections. HIV infections, caused by the human immunodeficiency virus (HIV), compromise the immune system’s capacity to combat infections and illnesses. Such a surge in HIV infections can be traced back to unprotected sexual intercourse with an infected person, needle or syringe sharing, exposure to infected blood products, having multiple sexual partners, and pre-existing sexually transmitted infections amidst a weakened immune system. AIDS management assists those with HIV infections through strategies like early diagnosis, increased access to apt antiretroviral therapies, improved prevention measures, and fortified healthcare systems, which aid in efficient control over the virus’s circulation. For example, the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, revealed data in November 2024 showing 112,883 HIV diagnoses in 2023 across 47 out of 53 countries, including 24,731 cases reported in the European Union/European Economic Area (EU/EEA). The overall crude HIV diagnosis rate increased by 2.4% compared to the 12.4 per 100,000 population rate in 2022, registering at 12.7 per 100,000 population. Hence, this surge in HIV infections is a significant propellant for the acquired immunodeficiency syndrome (AIDS) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp
How Is the Acquired Immunodeficiency Syndrome (AIDS) Market Segmented by Several Divisions?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
What are the Emerging Market Trends Driving the Growth of the Acquired Immunodeficiency Syndrome (AIDS) Industry?
Leading firms in the Acquired Immunodeficiency Syndrome (AIDS) market are prioritising the creation of innovative therapies such as long-acting injectables. These not only enhance patient conformity but also lower the dosing frequency, offering a more practical option than daily oral antiretroviral treatments. Long-acting injectables are drugs provided through injection, designed to gradually release their active ingredients over an elongated period, necessitating less regular dosing than traditional oral medications. For instance, in January 2025, GSK plc., a pharmaceutical entity based in the UK, received approval from the European Commission for Vocabria (cabotegravir) plus Rekambys (rilpivirine), a long-acting injectable treatment. It is sanctioned for use in patients as young as 12 years old who are affected by HIV and can be administered every one or two months via intramuscular injection, as per the specific treatment strategy. With its long-acting nature, compliance rates may be heightened among adolescents who find maintaining daily pill routines challenging.
Access The Full Report Here:
Which Regions Are Driving Growth in the Acquired Immunodeficiency Syndrome (AIDS) Market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076
This Report Delivers Insight On:
1. How big is the acquired immunodeficiency syndrome (aids) market, and how is it changing globally?
2. Who are the major companies in the acquired immunodeficiency syndrome (aids) market, and how are they performing?
3. What are the key opportunities and risks in the acquired immunodeficiency syndrome (aids) market right now?
4. Which products or customer segments are growing the most in the acquired immunodeficiency syndrome (aids) market?
5. What factors are helping or slowing down the growth of the acquired immunodeficiency syndrome (aids) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model